Evolving Paradigms in Triple-Negative Breast Cancer: Conclusion

Evolving Paradigms, Triple Negative Breast Cancer, Volume 2, Issue 1

The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis.

The treatment of TNBC continues to be a challenge for physicians because of its limited treatment options, the dearth of approved targeted therapies, high mortality, and poor prognosis. Patients and physicians are limited to chemotherapy that targets DNA repair complexes,p53, and cell proliferation by using anthracycline-based, platinum-based, and taxane-based treatment regimens.1However, research into targeted therapies for TNBC is robust. Further understanding of gene expression in breast cancer has led to classifications in TNBC that may help guide research into targeted therapies.21